Jason Berman

CEO, CHEO Research Institute

Role: Scientist

Site: CDL-Toronto

Stream: Health

My laboratory is expert in generating zebrafish models of childhood cancer using both transgenic and xenograft approaches. We have pioneered primary leukemia xenografts into zebrafish embryos and have optimized assays to evaluate proliferation and cell migration of both leukemia cells and solid tumors. We are also the first lab to identify zebrafish mast cells and demonstrate conserved development and function to their mammalian counterparts. I have clinical expertise in childhood myeloid disease and am co-chair of AAML1531, a Phase III Children’s Oncology Group study of risk-stratified therapy for AML in Down syndrome,. My goal is to translate findings from our zebrafish models to improve the outcome for childhood cancers, mast cell diseases and other rare genetic disorders. In August 2019, I relocated my laboratory to the Univesity of Ottawa following my recruitment to the Children’s Hospital of Eastern Ontario (CHEO) as CEO and Scientific Director of the CHEO Research Institute and Vice President Research at CHEO.